Display options
Cite
Jørgensen JO, Feldt-Rasmussen U, Frystyk J, et al. Medicinsk kombinationsbehandling af akromegali med somatostatinanalog og en vaeksthormon-receptorantagonist. [Medical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist]. Ugeskr Laeger. 2007;169(10):911-3
Jørgensen, J. O., Feldt-Rasmussen, U., Frystyk, J., Chen, J. W., Kristensen, L. �. �., Hagen, C., & Ørskov, H. (2007). Medicinsk kombinationsbehandling af akromegali med somatostatinanalog og en vaeksthormon-receptorantagonist. [Medical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist]. Ugeskrift for laeger, 169(10), 911-3.
Jørgensen, Jens Otto Lunde, et al. "Medicinsk kombinationsbehandling af akromegali med somatostatinanalog og en vaeksthormon-receptorantagonist." [Medical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist]. Ugeskrift for laeger vol. 169,10 (2007): 911-3.
Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H. Medicinsk kombinationsbehandling af akromegali med somatostatinanalog og en vaeksthormon-receptorantagonist. [Medical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist]. Ugeskr Laeger. 2007 Mar 05;169(10):911-3. Danish. PMID: 17359735.
Copy Download .nbib Format: NLM
Share it on

Ugeskr Laeger. 2007 Mar 05;169(10):911-3.

[Medical co-treatment af acromegaly with a somatostatin analogue and a growth hormone receptor antagonist].

Ugeskrift for laeger

[Article in Danish]
Jens Otto Lunde Jørgensen, Ulla Feldt-Rasmussen, Jan Frystyk, Jian-Wen Chen, Lars Østergård Kristensen, Claus Hagen, Hans Ørskov

Affiliations

  1. Arhus Universitetshospital, Arhus Sygehus, Medicinsk Afdeling M, Arhus C. [email protected]

PMID: 17359735

Abstract

We tested the effect of co-treatment of acromegaly with a somatostatin analogue (SA) and a growth hormone receptor antagonist (GHA). Eleven patients underwent: 1) conventional treatment with SA, 2) discontinued treatment, 3) 6 weeks treatment with GHA (10 mg), 4) 6 weeks treatment with GHA (15 mg), 5) 3 months combined SA and GHA. Circulating IGF-I was lowered by GHA and more so with combined treatment. Treatment with GHA increased endogenous GH levels, which was partly reversed by combined treatment. Plasma glucose levels were highest during SA treatment and lowest with GHA. Co-treatment of acromegaly with SA and GHA is a promising concept.

Publication Types